BioStock: Cyxone comments on scientific T20K article

This week, the scientific journal Biomedicine & Pharmacotherapy published an article regarding T20K, Cyxone's drug candidate in multiple sclerosis. Behind the article are Christian Gruber and researchers at the Medical University of Vienna. The authors report findings indicating that T20K may have an effect on anaplastic large cell lymphoma. BioStock contacted Cyxone's acting CEO Carl-Magnus Högerkorp to find out more.

Read the interview with Cyxone's acting CEO Carl-Magnus Högerkorp at biostock.se:

https://www.biostock.se/en/2022/08/cyxone-comments-on-scientific-t20k-article/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/